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Objectives: The aim was to evaluate the cross-sectional and long-term triage performance of FAM19A4/
miR124-2 methylation analysis in human papillomavirus (HPV)-based cervical screening.
Methods: We conducted a post hoc analysis within a Dutch population-based HPV-positive study cohort
of women aged 30e60 years (n ¼ 979). Cross-sectional cervical intraepithelial neoplasia (CIN) 3þ
sensitivity, specificity, positive predictive value and negative predictive value as well as cumulative
CIN3þ or cervical cancer risks after 9 and 14 years were compared for three baseline triage strategies: (1)
cytology, (2) FAM19A4/miR124-2 methylation analysis and (3) combined FAM19A4/miR124-2 methylation
with cytology.
Results: CIN3þ sensitivity of FAM19A4/miR124-2 methylation analysis was similar to that of cytology
(71.3% vs 76.0%, ratio 0.94, 95% CI 0.84 to 1.05), at a lower specificity (78.3% vs 87.0%, ratio 0.90, 95% CI
0.86 to 0.94). Combining FAM19A4/miR124-2 methylation analysis with cytology resulted in a CIN3þ
sensitivity of 84.6% (95% CI 78.3 to 90.8) at a specificity of 69.6% (95% CI 66.5 to 72.7). Similar 9- and 14-
year CIN3þ risks for baseline cytology-negative women and baseline FAM19A4/miR124-2 methylation-
negative women were observed, with risk differences of e0.42% (95% CI e2.1 to 1.4) and e0.07% (95%
CI e1.9 to 1.9), respectively. The 14-year cumulative cervical cancer incidence was significantly lower for
methylation-negative women compared to cytology-negative women (risk difference 0.98%, 95% CI 0.26
to 2.0).
Discussion: FAM19A4/miR124-2 methylation analysis has a good triage performance on baseline
screening samples, with a cross-sectional CIN3þ sensitivity and long-term triage-negative CIN3þ risk
equalling cytology triage. Therefore, FAM19A4/miR124-2 methylation analysis appears to be a good and
objective alternative to cytology in triage scenarios in HPV-based cervical screening. F.J. Vink, Clin
Microbiol Infect 2020;▪:1
© 2020 European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd. All
rights reserved.Introduction
A persistent infection with a high-risk type of human papillo-
mavirus (HPV) is an essential step in the development of cervicalrdam UMC, Vrije Universiteit
e Boelelaan 1117, 1081 HV,
l (D.A.M. Heideman).
biology and Infectious Diseases. P
19A4/miR124-2 methylation a
hort, Clinical Microbiology acancer and its precursor lesions (cervical intraepithelial neoplasia;
CIN) [1]. This insight has led to conversion of the cervical screening
programme from primary cytology to primary HPV testing in
several European countries and Australia, and other countries are
considering this transition as well [2]. Benefits of primary HPV-
based screening include the high sensitivity and negative predic-
tive value (NPV) for the detection of high-grade CIN and cervical
cancer [3,4], and the compatibility with self-sampling [5].
Furthermore, HPV testing provides better protection againstublished by Elsevier Ltd. All rights reserved.
nalysis as a triage test for HPV-positive women: cross-sectional and
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HPV testing also detects transient, clinically irrelevant HPV in-
fections, resulting in a lower specificity than cytology. Triage testing
of HPV-positive women is needed to identify the women with
clinically relevant disease, in order to reduce unnecessary referral
for colposcopy [6].
Different triage strategies for HPV-positive women have been
evaluated in recent years, including microscopy-based strategies
like cytology and p16/Ki-67 dual stained cytology, and molecular
triage tests such as HPV genotyping and viral or host cell DNA
methylation analysis [7,8]. Currently, cytology is the most
commonly used triage test for HPV-positive women [9,10]. How-
ever, cytology relies on a subjective interpretation, and is highly
dependent upon experienced cytologists for correct evaluation.
Furthermore, it has been reported that cytological screening per-
formed with knowledge of HPV status can result in a loss in spec-
ificity [11]. These drawbacks underline the need for an alternative,
reproducible and objective triage test. Host cell DNA methylation
analysis is increasingly being studied as a potential triage test with
these characteristics, and demonstrated promise for the detection
of high-grade CIN and cervical cancer in triage setting for HPV-
positive women [12].
Host cell DNA methylation is a frequently observed epigenetic
phenomenon in cervical carcinogenesis following a persistent HPV
infection [1]. The hypermethylation of CpG-rich gene promoter
regions of human genes, often tumour suppressor genes, can lead
to gene silencing, which contributes to cancer development.
Methylation analysis of FAM19A4 (family with sequence similarity
19 (chemokine (CeC)-motif)-like), member A4) (also known as
TAFA4 (TAFA chemokine like family member 4)) and miR124-2
(microRNA 124-2) genes has shown good reproducibility [13], a
high sensitivity for CIN3þ [14,15] and detects nearly all cervical
carcinomas [16]. Initial longitudinal studies illustrated that triage of
HPV-positivewomenwith FAM19A4/miR124-2methylation analysis
provides at least similar long-term risk stratification for cervical
cancer and CIN3 as cytology over 14 years [17,18], substantiating the
triage capability of the FAM19A4/miR124-2 marker panel.
Here, we present a post hoc analysis within a large HPV-positive
population-based Dutch screening cohort to assess the cross-
sectional performance and long-term triage-negative CIN3þ and
cervical cancer risks of baseline FAM19A4/miR124-2 methylation
analysis. Data were compared with cytology triage testing
following a HPV-positive test (threshold borderline dyskaryosis or
atypical squamous cells of undetermined significance) and to a
combined (i.e. methylation with cytology) triage test strategy.
Materials and methods
Study population
This study is a post hoc analysis of baseline FAM19A4/miR124-2
methylation analysis (QIAsure Methylation Test®, QIAGEN, Hilden,
Germany) within the VUSA-Screen cohort, a population-based
cervical screening cohort study carried out in the setting of the
Dutch screening programme between October 2003 and August
2005. The design has been described previously [19]. For this study,
we selected all baseline high-risk HPV-positive women (n ¼ 1303).
All participants provided written informed consent. The VUSA-
Screen study was approved by the Ministry of Public Heath
(2002/02-WBO; ISBN10:90-5549-452-6) and registered in the trial
register (NTR215, ISRCTN64621295). Histopathological and cyto-
pathological follow-up data of women participating in the VUSA-
Screen study were collected through the nationwide network and
registry of histopathology and cytopathology (PALGA) [20]. Results
were retrieved until 12 December 2017, resulting in up to 14 yearsPlease cite this article as: Vink FJ et al., FAM19A4/miR124-2 methylation a
longitudinal data from a Dutch screening cohort, Clinical Microbiology aof follow-up. Detailed study procedures within the VUSA-Screen
study and details on methylation analysis are described in the
supplementary material.
Data and statistical analysis
The endpoint was CIN grade 3 or worse (CIN3þ). Study end-
points were assessed based on the histological outcome of the
colposcopy-directed biopsy, or, if classified worse, on the histology
result of the specimen excised by large loop excision of the trans-
formation zone (LLETZ), conization or hysterectomy. Three-year
follow-up results were used as cross-sectional study endpoint, as
previously described [19]. For the long-term CIN3 and cervical
cancer risks we used 9- and 14-year follow-up results, equally
defined as in long-term evaluations of the Dutch POBASCAM study
[21].
We considered the following three baseline triage strategies for
HPV-positive women: (1) cytology, (2) FAM19A4/miR124-2
methylation analysis and (3) combined FAM19A4/miR124-2
methylation analysis with cytology. Strategy 1 was labelled positive
if the result was borderline or mild dyskaryosis or worse. Strategy 2
was labelled positive if the QIAsure Methylation Test® result was
methylation-positive. Strategy 3 was labelled positive in case the
QIAsure Methylation Test® result was methylation-positive and/or
cytology was borderline or mild dyskaryosis or worse. Proportions
of methylation test positivity within baseline cytology results were
compared using chi-square tests.
Cross-sectional analysis
Sensitivity, specificity, positive predictive value (PPV) and
negative predictive value (NPV) for the detection of CIN3þ were
calculated with 95% confidence intervals (95% CI). Loss to follow-up
among baseline cytology-negative women was accounted for by
imputing observed proportions of histological outcomes from
women with complete cross-sectional follow-up into women with
incomplete cross-sectional follow-up (please see supplementary
material). Differences between baseline triage strategies were
calculated using the relative sensitivity and relative specificity (i.e.
ratio of the sensitivity or specificity of one test to the sensitivity or
specificity of another test, respectively). A difference was consid-
ered significant if the 95% CI of the relative sensitivity or specificity
was entirely below or above 1.
Longitudinal analysis
Follow-up data until 14 years after inclusion were retrieved.
Cumulative 9- and 14-year histology outcomes were categorized
using worst histology outcome. Details on censoring and exclusion
rules are described in thesupplementary material. Cumulative in-
cidences of CIN3þ and cervical cancer, stratified by different triage
strategies at baseline, were estimated using the KaplaneMeier
method and were compared by calculating risk differences after 9
and 14 years of follow-up. We constructed 95% CIs for the risk
differences via Bootstrap in R (version 3.6.1, Vienna, Austria). If the
95% CI did not contain the value 0, the difference was considered
significant. All other analyses were carried out with IBM SPSS
(version 24.0, IBM Corp, Armonk, NY, USA), STATA (version 14.1,
Texas, USA) and Excel.
Results
Study cohort and baseline findings
The study flowchart is shown in Fig. 1. Of the 1303 HPV-positive
women, 236 were excluded due to insufficient leftover material for
methylation analysis and 61were excluded because no longitudinalnalysis as a triage test for HPV-positive women: cross-sectional and
nd Infection, https://doi.org/10.1016/j.cmi.2020.03.018
Fig. 1. Study flowchart showing baseline cytology and FAM19A4/miR124-2 methylation analysis results and cross-sectional 3-year cumulative histology endpoints with imputed
study endpoints to account for incomplete follow-up during the cross-sectional study period. HPV, human papillomavirus; Cyto-, cytology-negative; Cytoþ, cytology-positive; MM-,
methylation-negative; MMþ, methylation-positive; CIN3, cervical intraepithelial neoplasia grade 3; CC, cervical cancer. Adenocarcinoma in situ was counted as CIN3.
F.J. Vink et al. / Clinical Microbiology and Infection xxx (xxxx) xxx 3follow-up data were retrieved through PALGA. Another 27 women
were excluded due to an invalid FAM19A4/miR124-2 methylation
test result, leaving 979 HPV-positive women (median age of
35 years; range 29e61 years) in the final analysis. No differences
were found in baseline characteristics (age, cytology results, CIN3þ
proportions) between the study population used for final analysis
(n ¼ 979 women) and the excluded population (n ¼ 324 women).
Of the 979 HPV-positive women, 276 (28.2%) tested methylation
positive in their baseline cervical smear. Baseline cytology results
were normal in 771 (78.8%), borderline or mild dyskaryosis in 123
(12.6%) and moderate dyskaryosis or worse in 85 (8.7%) women.
The proportion of women with a methylation-positive test was
20.6% (159/771) in women with normal cytology, 38.2% (47/123) in
women with borderline or mild dyskaryosis and 82.4% (70/85) in
women with moderate dyskaryosis or worse (p < 0.0001).
Cross-sectional analysis
During 3 years of follow-up, 109 CIN3 and six cervical carci-
nomas were detected (Fig. 1). FAM19A4/miR124-2 methylation
positivity proportion in the baseline HPV-positive cervical smears
increased significantly from 21.9% (189/864) in controls to 74.3%
(81/109) in women with CIN3 and 100% (6/6) in women withTable 1
Sensitivity, specificity, PPV, NPV and colposcopy referral rate for CIN3þ, of three baselin
Triage algorithm Sensitivity % 95% CI Specificity %
CIN3 1 Cytology 76.0 68.5e83.4 87.0
2 FAM19A4/miR124-2 methylation 71.3 63.4e79.1 78.3
3 FAM19A4/miR124-2 methylation
and/or cytology
84.6 78.3e90.8 69.6
The colposcopy referral rate was calculated as the proportion of HPV-positive women wh
positive predictive value; NPV, negative predictive value; 95% CI, 95% confidence interva
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ities, PPVs and NPVs as well as referral rates for CIN3þ, calculated
for the three baseline triage strategies. The sensitivity of FAM19A4/
miR124-2 methylation analysis (Strategy 2) was similar to that of
cytology (Strategy 1) (71.3% vs 76.0%, ratio 0.94, 95% CI 0.84 to 1.05),
at a lower specificity (78.3% vs 87.0%, ratio 0.90, 95% CI 0.86 to 0.94).
Combining FAM19A4/miR124-2 methylation analysis with cytology
(Strategy 3) showed a CIN3þ sensitivity of 84.6% (95% CI 78.3 to
90.8) at a specificity of 69.6% (95% CI 66.5 to 72.7).
Longitudinal analysis
Fig. 2 shows KaplaneMeier curves with the cumulative inci-
dence for CIN3þ stratified per baseline negative triage strategy.
Cytology-negative women and methylation-negative women had
equal cumulative CIN3þ incidences at 9 years after baseline (9.4%
vs 9.8%, risk difference e0.42%, 95% CI e2.1 to 1.4) and at 14 years
after baseline (12.8% vs 12.8%, risk differencee0.07%, 95% CI e1.9 to
1.9). Combining FAM19A4/miR124-2 methylation analysis with
cytology screening resulted for triage-negative women in a cu-
mulative CIN3þ incidence of 7.7% (95% CI 5.5 to 9.9) at 9 years and
10.9% (95% CI 8.0 to 13.7) at 14 years after baseline. The 14-year
cumulative cervical cancer incidence was 2.0% for cytology-e triage strategies for HPV-positive women
95% CI PPV % 95% CI NPV % 95% CI Colposcopy
referral rate %
95% CI
84.7e89.2 46.6 39.9e53.4 96.0 94.6e97.4 21.2 8.7e23.8
75.5e81.0 33.0 27.4e38.5 94.8 93.1e96.4 28.2 25.4e31.0
66.5e72.7 29.4 24.8e34.1 96.8 95.4e98.2 37.5 34.5e40.5
o had a positive triage test result. Adenocarcinoma in situwas counted as CIN3. PPV,
l.
nalysis as a triage test for HPV-positive women: cross-sectional and
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Fig. 2. Cumulative incidence for CIN3þ stratified per triage strategy. CIN3þ, cervical
intraepithelial neoplasia grade 3 or worse.
F.J. Vink et al. / Clinical Microbiology and Infection xxx (xxxx) xxx4negative women and 1.1% for methylation-negative women (risk
difference 0.98%, 95% CI 0.26 to 2.0, Fig. 3).Discussion
In the present study, we evaluated the cross-sectional and lon-
gitudinal triage performance of single or combined cytology and
FAM19A4/miR124-2 methylation analysis as baseline triage strate-
gies in a large population-based HPV-positive screening cohort.
Cross-sectional performance of FAM19A4/miR124-2methylation
analysis was comparable to cytology, with similar CIN3þ sensitivity
at a lower specificity. Both single test triage strategies (Strategy 1
and Strategy 2) showed PPV estimates appropriate for direct col-
poscopy referral, and NPV estimates that would require repeat
testing according to accepted safety thresholds [22,23]. Combining
the single test strategies (Strategy 3) raises the sensitivity with a
slight decrease in specificity, but also increases the burden of
screening with a relatively low PPV and markedly increased col-
poscopy referral rates. Strategy 3 could be visualized in either a co-
testing strategy at baseline, or in a strategywith FAM19A4/miR124-2Fig. 3. Cumulative incidence for cervical cancer stratified per triage strategy.
Please cite this article as: Vink FJ et al., FAM19A4/miR124-2 methylation a
longitudinal data from a Dutch screening cohort, Clinical Microbiology amethylation analysis at baseline and subsequent cytology testing
after 6e12 months for methylation-negative women. This
sequential algorithm would make baseline molecular screening
feasible, with the benefit of compatibility with self-sampling, and
yield a possible increase in specificity due to the expected clearance
of HPV and associated regression of lesions within 6e12 months.
Our longitudinal data show that women with a baseline negative
FAM19A4/miR124-2 methylation test result have equal 9- and 14-
year risks for developing CIN3þ in comparison to baseline
cytology-negativewomen. Combining these two strategies resulted
in even lower 9- and 14-year cumulative incidences. Altogether, our
data underline that methylation analysis may be used to build
robust triage algorithms with more objective stratification of
women referred for colposcopy versus re-testing compared with
cytology [24,25].
Our cross-sectional data are consistent with recent evaluations
of several methylation markers, with sensitivities for CIN3þ of
71.1% (95% CI 65.7 to 76.0) and a PPV of 35.0% (95% CI 28.9 to 41.6) at
a set specificity of 70% [12]. The longitudinal data of our study are
consistent with the results of evaluations of the 9- and 14-year
CIN3þ risks for women triaged by FAM19A4/miR124-2 methyl-
ation within the Dutch POBASCAM study [18]. In contrast to the
POBASCAM study, study management in the VUSA-Screen study
was based on both cytology and HPV testing, making it feasible to
report cross-sectional CIN3þ risks after a negative triage test.
The FAM19A4/miR124-2 methylation positivity proportion for
cervical carcinomas diagnosed within the different screening
rounds were in line with long-term evaluations of the Dutch
POBASCAM study [17], though numbers in this study were limited.
Consistent with the above-mentioned study, a lower 14-year cer-
vical cancer risk among baseline methylation-negative women
than cytology-negativewomenwas found. As a high cross-sectional
sensitivity and low long-term NPV for cervical cancer ensures the
safety of a triage strategy, these findings are of great importance in
the search for molecular triage strategies.
Despite the fact that similar cross-sectional sensitivities are
observed, methylation analysis and cytology in part detect different
CIN lesions [1,25,26]. It has been shown that FAM19A4methylation
analysis in cervical smears tends to be more competent than
cytology in detecting more advanced CIN2/3 as defined by a
persistent HPV infection with a duration over 5 years [14]. A recent
study reports that about three-quarters of cervical smears of
women with CIN3 display a cancer-like methylation-high pattern,
suggestive for a higher risk of progression to cervical cancer [27].
These results corroborate with the finding that without interven-
tion only a subset of CIN3 will progress to cancer over a long time
period. It can be reasoned that methylation analysis allows to
distinguish the need of immediate treatment versus active sur-
veillance. This could prevent overtreatment and the associated
cervical morbidity, which is especially relevant for women of
childbearing age. Indeed, it was recently shown that a methylation
panel consisting of host cell and viral genes has the ability to
identify progressive CIN2 lesions in young women [28]. Additional
studies are presently ongoing to validate these findings [29].
The main strengths of our study are its large sample size, the
long follow-up period of 14 years and the setting within the Dutch
cervical screening programme. In addition, we used a standardized
FAM19A4/miR124-2 methylation assay. A limitation of this study
might be seen in the high cross-sectional loss to follow-up among
women with normal cytology at baseline. To account for this,
observed proportions of histological outcomes from women with
complete follow-up were imputed to women with incomplete
follow-up. In the original study, management was based on HPV
and cytology results. This verification bias may have led to an un-
derestimation of the performance of FAM19A4/miR124-2nalysis as a triage test for HPV-positive women: cross-sectional and
nd Infection, https://doi.org/10.1016/j.cmi.2020.03.018
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present, given that cross-sectional study endpoints included
follow-up up to 3 years after baseline and baseline colposcopy
referral depended on the baseline cytology result. However, the
median time to CIN3þ diagnosis was 77 days and only nine cross-
sectional detected CIN3þ lesions were diagnosed between 2 and
3 years after baseline, indicating that this possible bias is limited.
In The Netherlands, cytology is well quality assured, and the
accuracy of cytology reading is high [30], explaining the good
performance of cytology triage testing in this cohort. Of note,
quality of cytology varies widely among countries and can be
difficult to retain, especially in less developed countries. In addi-
tion, in this study cytologywas readwithout prior knowledge of the
HPV result. The advantages afforded by DNA methylation analysis
are the molecular basis, making triage testing automatable and less
prone to training and interpretational errors than cytology.
Methylation-based triage has recently shown to perform robust
and reproducible in different laboratory contexts [13]. Another
advantage of methylation analysis over cytology, is the compati-
bility with self-collected samples [24], which may allow for full
molecular self-screening. While current methylation technologies
may not yet be suitable for large-scale implementation, techno-
logical advances and ongoing development of methylation assays is
expected to result in automated and user-friendly assays, suitable
for high-throughput testing in laboratories with HPV testing facil-
ities. With comparable performance to cytology, methylation-
based triage testing could become a reproducible and robust
triage algorithm in many countries.
The data presented in this study confirm that FAM19A4/miR124-
2methylation analysis can be considered as an objective alternative
to cytology in triage scenarios in HPV-based cervical screening.
These findings highlight the potential of methylation testing to
realize full molecular screening in future.Transparency declaration
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